"Appetite Depressants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that are used to suppress appetite.
| Descriptor ID |
D001067
|
| MeSH Number(s) |
D27.505.954.427.140.155
|
| Concept/Terms |
Appetite Depressants- Appetite Depressants
- Depressants, Appetite
- Anorectics
- Anorexic Drugs
- Drugs, Anorexic
- Appetite Suppressants
- Suppressants, Appetite
- Appetite-Depressing Drugs
- Appetite Depressing Drugs
- Drugs, Appetite-Depressing
- Appetite-Suppressant Drugs
- Appetite Suppressant Drugs
- Drugs, Appetite-Suppressant
- Anorectic Agents
- Agents, Anorectic
- Anorexigenic Drugs
- Drugs, Anorexigenic
|
Below are MeSH descriptors whose meaning is more general than "Appetite Depressants".
Below are MeSH descriptors whose meaning is more specific than "Appetite Depressants".
This graph shows the total number of publications written about "Appetite Depressants" by people in this website by year, and whether "Appetite Depressants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Appetite Depressants" by people in Profiles.
-
Kim GW, Lin JE, Blomain ES, Waldman SA. New advances in models and strategies for developing anti-obesity drugs. Expert Opin Drug Discov. 2013 Jun; 8(6):655-71.
-
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013 Feb; 33(1):118-20.
-
Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring). 2011 Jul; 19(7):1325-34.
-
Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther. 2010 Jun; 87(6):652-62.
-
Lieberman JA. Effectiveness of sibutramine. J Fam Pract. 2002 Oct; 51(10):863; author reply 863, 867.
-
Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, R?ssner S, Saris W, Van Gaal L, James W, Goulder M. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes Relat Metab Disord. 2001 Apr; 25(4):496-501.
-
James WP, Astrup A, Finer N, Hilsted J, Kopelman P, R?ssner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000 Dec 23-30; 356(9248):2119-25.
-
Sobel RM. Ruptured retroperitoneal aneurysm in a patient taking phentermine hydrochloride. Am J Emerg Med. 1999 Jan; 17(1):102-3.
-
Alexander JH, Greenbaum AB, Hudson MP, Kong DF, Miller JM, Tung CY, Whellan DJ. Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. Am Heart J. 1998 Jul; 136(1):176-9.
-
Leo PJ, Hollander JE, Shih RD, Marcus SM. Phenylpropanolamine and associated myocardial injury. Ann Emerg Med. 1996 Sep; 28(3):359-62.